624 results on '"Kito Y"'
Search Results
2. Total Voltage Drops in Electrode Fall Regions of High Pressure Arcs between Electrodes of Cu-W, Cu, Fe, Ti, C and W in Current Range up to 20000A
3. Capsule Micromechanism Driven by Impulse
4. 126P Late line FOLFOX therapy after prior cisplatin-based regimen in advanced esophageal squamous cell carcinoma: A multi-institutional retrospective study
5. 1224P Final analysis of clinical outcomes in the DELIVER trial: Observational study of nivolumab treatment in advanced gastric cancer (JACCRO GC-08)
6. 389P Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST)
7. 528P The randomized phase III study of bi-weekly trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) vs. FTD/TPI monotherapy for chemorefractory metastatic colorectal cancer (mCRC): 1-year follow-up updated data from JCOG2014 (ROBiTS)
8. 522P Impact of age and single heterozygous UGT1A1 on the safety and efficacy of first-line FOLFIRI or FOLFOXIRI in combination with ramucirumab (RAM) for metastatic colorectal cancer (mCRC): Subgroup analyses of WJOG9216G (RECAST)
9. 518MO Update analysis of the randomized phase II study comparing FOLFIRI plus ramucirumab (RAM) versus FOLFOXIRI plus RAM as first-line treatment for patients with metastatic colorectal cancer: WJOG9216G (RECAST)
10. SO-8 Soluble programmed cell death ligand 1 associated with clinical outcome in gastric cancer patients treated with nivolumab: Blood based biomarker analysis of DELIVER trial (JACCRO-GC08AR)
11. Configuration-dependent controllability of flexible manipulators
12. Design study of a HTS cable in Yokohama project
13. O-13 Gut microbiome to predict survival time in advanced gastric cancer treated with nivolumab: The DELIVER trial (JACCRO GC-08)
14. P-56 A multicenter prospective translational study using circulating tumor DNA to identify acquired genomic alterations in recurrent gastric or gastroesophageal junction adenocarcinoma in patients who received curative-intent treatment (Liquid-GEAR)
15. 1585P The impact of platinum-induced peripheral neuropathy (PN) in first-line treatment on PN and efficacy in second-line paclitaxel (PTX)-based chemotherapy for unresectable advanced gastric cancer (AGC): A prospective observational multicenter study - IVY study
16. 1547P SNP discovery based on transcriptome sequencing of whole blood RNA to find predictive biomarkers for nivolumab in gastric cancer
17. 1549P A prospective study of circulating tumor DNA (ctDNA) genomic profiling in gastric or gastroesophageal junction (GEJ) cancer patients with recurrence after adjuvant chemotherapy: Liquid-GEAR trial
18. A new HTS cable project in Japan
19. SO-30 RAS status in circulating-tumor DNA after chemotherapy in RAS-mutant mCRC: The RASMEX study (JACCRO CC-17)
20. P-80 Analysis of plasma angiogenesis factors on the efficacy of FOLFIRI plus ramucirumab and FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer from WJOG9216G randomized phase II study
21. An Open-label Single-arm Trial of a Novel Extramedullary Guide Coordinated with 3D Surgical Assistive Software for Total Knee Arthroplasty
22. Skin recruitment of monomyeloid precursors involves human herpesvirus-6 reactivation in drug allergy
23. Characterization of a malignant T-cell line established from a rare case of CD8+CD56+ Sézary syndrome
24. CD8+ Sézary syndrome with interleukin-22 production modulated by bacterial sepsis
25. Capsule Micromechanism Driven by Impulse
26. Spontaneous electrical activity of fibroblast-like cells: 002
27. LBA-4 Updated analysis of DELIVER trial (JACCRO GC-08): A large observational/translational study of nivolumab treatment in advanced gastric cancer
28. Effects of dopamine on veins in humans: comparison with noradrenaline and influence of age
29. A novel yeast gene, RHK1, is involved in the synthesis of the cell wall receptor for the HM-1 killer toxin that inhibits β-1,3-glucan synthesis
30. Molecular cloning, purification and characterization of two endo-1,4-β-glucanases from Aspergillus oryzae KBN616
31. Factors modifying the frequency of spontaneous activity in gastric muscle
32. Transmission loss of Prospective Power Transmission Model System Integrated under Superconducting Environment
33. Development of the prospective power transmission model system integrated under superconducting environment - PROMISE
34. Creepage discharge propagation in air and SF6 gas influenced by surface charge on solid dielectrics
35. No-tolerant Consumers, Information Treatments, and Demand for Stigmatized Foods: the Case of Fukushima Nuclear Power Plant Accident in Japan
36. Interim analysis of an observational/translational study for nivolumab treatment in advanced gastric cancer: JACCRO GC-08 (DELIVER trial)
37. Randomized phase II study of FOLFIRI plus ramucirumab (Rmab) versus FOLFOXIRI plus Rmab as first-line treatment for patients with metastatic colorectal cancer (mCRC): WJOG9216G
38. Development of spinel-type ZnGa2O4 thin-film transistor and its application to flexible devices
39. Update analysis of phase Ib study of FOLFOXIRI plus ramucirumab as first-line therapy for patients with metastatic colorectal cancer
40. Safety analysis of phase Ib study of FOLFOXIRI plus ramucirumab as first-line therapy for patients with metastatic colorectal cancer
41. 217TiP Dose-finding phase Ib study of FOLFOXIRI plus ramucirumab as first-line therapy for patients with metastatic colorectal cancer
42. 217TiP Dose-finding phase Ib study of FOLFOXIRI plus ramucirumabas first-line therapy for patients with metastatic colorectal cancer
43. 820P - Interim analysis of an observational/translational study for nivolumab treatment in advanced gastric cancer: JACCRO GC-08 (DELIVER trial)
44. Risk factors for esophageal fistula in esophageal squamous cell carcinoma invading adjacent organs (T4b) treated with definitive chemoradiotherapy
45. 165P Neutropenia as a predictive factor in patients with metastatic colorectal cancer treated with TAS-102
46. 169P Serum CA19-9 response is an early predictive marker for the efficacy of regorafenib in refractory metastatic colorectal cancer
47. 606TiP - Randomized phase II study of FOLFIRI plus ramucirumab (Rmab) versus FOLFOXIRI plus Rmab as first-line treatment for patients with metastatic colorectal cancer (mCRC): WJOG9216G
48. Thermal and electrical properties of heavy current arc column in SF6 gas
49. 2125 Evaluation timing and cutoff value of tumor size (TS) ratio by using tumor growth inhibition (TGI) model to predict overall survival (OS) in metastatic colorectal cancer (mCRC) patients received first-line chemotherapy (CTx)
50. A Case of Felty’s Syndrome Associated with Skin Ulcers and Extranodal NK/T-cell Lymphoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.